Traws Pharma files Form D for up to $50 million equity facility

Traws Pharma, Inc., based in Newtown, Pennsylvania, filed a Form D notice with the Securities and Exchange Commission dated November 5, 2026, for a new offering of equity securities. The filer's CIK number traces to Onconova Therapeutics, Inc., which is listed as a previous name of the issuer now named Traws Pharma, Inc.¹

The filing describes the raise as a committed equity facility under which the issuer has the right, in its sole discretion, to sell to the investor up to an aggregate of $50,000,000 of the issuer's common stock from time to time, subject to certain limitations.¹ As of the filing date, the total amount sold was $0, with the full $50,000,000 remaining to be sold.¹

The offering relies on the Rule 506(b) exemption¹ and is structured as equity securities. The type of securities offered is listed as equity.¹ The company stated the offering is not being made in connection with a business combination transaction such as a merger, acquisition, or exchange offer.¹

The filing lists one investor who has already invested in the offering.¹ The minimum investment accepted from any outside investor was listed as $0.¹ No sales commissions or finders' fees were reported, both listed as $0.¹ No proceeds were allocated for payments to executive officers, directors, or promoters named in the filing.¹

Related persons named in the filing include Iain Dukes as CEO and Director, Charles Parker as CFO, Jack E. Stover as Chair and Director, and additional directors Nikolay Savchuk, Trafford Clarke, Mary Teresa Shoemaker, John Leaman, and Werner Cautreels.¹ The notice was signed by Charles Parker, CFO, on November 5, 2026.¹

The issuer is classified under the biotechnology category within the health care industry group.¹ The company indicated it intends the offering to last more than one year.¹